Does the Choice of Statin Really Matter?

References

• . Lavie CJ, Milani RV, O'Keefe JH. Statin wars: emphasis on potency vs event reduction and safety? Mayo Clin Proc. 2007;82(5):539–542
   PubMed Web of Science ®Google Scholar
• . Maroo BP, Lavie CJ, Milani RV. Efficacy and safety of intensive statin therapy in the elderly. Am J Geriatr Cardiol. 2008;17(2):92–100
   PubMedGoogle Scholar
• . O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43(11):2142–2146
   PubMed Web of Science ®Google Scholar
• . Wiviott SD, Cannon CP, Marrow DA, Ray II, Pfeffer MA, Braunwald E; PROVE IT-TIMI 22 Investigators.Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy (errata in J Am Coll Cardiol 2006;47:472). J Am Coll Cardiol. 2005;46(8):1411–1416
   PubMed Web of Science ®Google Scholar
• . LaRosa JC, Grundy SM, Waters DD, ; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–1435
   PubMed Web of Science ®Google Scholar
• . Pedersen TR, Faegerman O, Kastelein JJ, . High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437–2445
   PubMed Web of Science ®Google Scholar
• . Maroo BP, Lavie CJ, Milani RV. Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike? Drugs Aging. 2008;25(8) 649–664
   PubMed Web of Science ®Google Scholar
• . O'Keefe JH, Carter MD, Lavie CJ, Bell DS. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin). Postgrad Med. 2009;121(3):113–118
   PubMed Web of Science ®Google Scholar
• . Rublee DA, Burke JP. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice. Postgrad Med. 2010;122(2):16–24
   PubMed Web of Science ®Google Scholar
• . Bybee KA, Lee JH, O'Keefe JH. Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. Curr Med Res Opin. 2008;24(4):1217–1229
   PubMed Web of Science ®Google Scholar
• . Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 1994;334(8934):1383–1389
   Google Scholar
• . Heart Protection Study Collaborative Group. MRG/BHF Heart protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360(9326):7–22
   PubMed Web of Science ®Google Scholar
• . Sever P, Dahlöf B, Puulter N, ; ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006;27(24):2982–2988
   PubMed Web of Science ®Google Scholar
• . Colhoun HM, Betteridge DJ, Durrington PN, ; CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–696
   PubMed Web of Science ®Google Scholar
• . Waters DD, Schwartz GG, Olsson AG, ; MIRACL Study Investigators. Effects of atorvastatin on stoke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation. 2002;106(13):1690–1695
   PubMed Web of Science ®Google Scholar
• . Amarenco P, Bogousslavsky J, Callahan A 3rd, ; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–559
   PubMed Web of Science ®Google Scholar
• . Koren MJ, Hunninghake DB; ALLIANCE Investigators.Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol. 2004;44(9):1772–1779
   PubMed Web of Science ®Google Scholar
• . Lavie CJ, Milani RV. High-dose atorvastatin in acute coronary and cerebrovascular syndromes. JACC Cardiovasc Interv. 2010;3(3):340–342
   PubMed Web of Science ®Google Scholar
• . Gibson CM, Pride YB, Hochberg CP, ; TIMI Study Group. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22) Substudy. J Am Coll Cardiol. 2009;54(24):2290–2295
   PubMed Web of Science ®Google Scholar
• . Hermann J. Peri-procedural myocardial injury: 2005 update. Eur Heart J. 2005;26(23):2493–2519
   PubMed Web of Science ®Google Scholar
• . Patti G, Pasceri V, Colonna A, . Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49(12):1272–1278
   PubMed Web of Science ®Google Scholar
• . Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J Am Coll Cardiol. 2009;54(6):558–565
   PubMed Web of Science ®Google Scholar
• . Kim JS, Kim J, Choi D, . Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment myocardial infarction: the (STATIN STEMI) trial. JACC Cardiovascular Interv. 2010;3(3):332–339
   PubMed Web of Science ®Google Scholar
• . Nissen SE. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA. 2004;292(11):1365–1367
   PubMed Web of Science ®Google Scholar
• . Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol. 2007;49(17):1753–1762
   PubMed Web of Science ®Google Scholar
• . Collins R, ; SEARCH investigators. Oral presentation at: American Heart Association; Orlando, FL; November 2009
   Google Scholar
• . US Food and Drug Administration. New FDA labeling for simvastatin. FDA News Alert. Assessed March 23, 2010
   Google Scholar
• . Krasuski RA, Doeppenschmidt D, Henry JS, . Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study. Mayo Clin Proc. 2005;80(9):1163–1168
   PubMed Web of Science ®Google Scholar
• . Jacobson TA, Wertz DA, Hoy T, Kuznik A, Grochulski D, Cziraky M. Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated. Mayo Clin Proc. 2008;83(12)1316–1325
   PubMed Web of Science ®Google Scholar
• . Simpson RJ, Signorovitch J, Birnbaum H, . Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population. Mayo Clin Proc. 2009;84(12):1065–1072
   PubMed Web of Science ®Google Scholar